HIGHLIGHTS
- who: Wengang Zhang from the Department of Medical Oncology, Qilu Hospital of Shandong University, Wenhuaxi Road, Jinan, Shandong, China have published the Article: ANK2 as a novel predictive biomarker for immune checkpoint inhibitors and its correlation with antitumor immunity in lung adenocarcinoma, in the Journal: (JOURNAL)
- what: In this study, the relationship between ANK2 mutation and ICIs efficacy in LUAD was analyzed through systematically collected and integrated clinical and genomic data from the cBioportal database (Hellmann et_al and Rizvi et_al cohorts). Notwithstanding, the study provided comprehensively predictive and prognostic evidence concerning ANK2 in LUAD for . . .
If you want to have access to all the content you need to log in!
Thanks :)
If you don't have an account, you can create one here.